Cardiac transplantation : an evolving practice by Manche, Alexander
Maltese Medical Journal, 1997; 9(2):4 

All rights reserved 

GUEST EDITORIAL 
Cardiac transplantation: an evolving practice 
Alexander Manche 
Co/Tespondence: Mr. A. Manche, Cardiothoracic Division, Department of Surgery. SI. Luke's Hospital. Gwardamangia. Malta. 
'The dream of the ancients has been the junction of 
portions of different individuals, not only to counteract 
.....oIII! disease, but also to combine the potentials of different 
species" [from a paper entitled "The Operation" by 
Christiaan Barnard following the first successful human 
cardiac transplant on December 3,1967 I] 
When Barnard performed the first orthotopic 
transplant he became an instant celebrity. By today's 
standards the method of retrieval was daring and fraught 
with risk. The donor was placed on bypass five minutes 
after cessatio~ of cilrdiac electrical activity and the heart 
was cooled," removed and transplanted using the 
technique des.cribed by Lower and Shumway 2. Louis 
Washkansky recovered but died 18 days later of 
'Pseudomonas pneumonia. Barnard performed his 
second transplant on January 2, 1968. This time the 
recipient, Philip Blaiberg, enjoyed a spectacular 
recovery. Barnard's widely acclaimed success 
encouraged several surgeons worldwide to attempt the 
procedure. That year, 102 transplants were carried out at 
17 centres world wide but with such disastrous results 
that further clinical transplantation all but ceased during 
the 1970s 3.4. The discovery of cyclosporine A by Borel 
et al 5 in 1970 together with laboratory and clinical 
investigation, performed principally at Stanford 
University, resulted in the emergence of cardiac 
transplantation as an accepted treatment modality for 
end-stage heart disease. Larsson 6 later showed that 
cyclosporine A, a fungal metabolite, selectively inhibited 
the production of interleukin 2, and at low doses, the 
induction of its receptors. Today it is the mainstay of 
immunosuppressive therapy, in combination with 
steroids and azathioprine. 
Another milestone in transplantation was achieved 
when in 1972, Judge Compton acquitted Dr. Richard 
Lower of "wrongful death" following the removal of a 
beating heart. The judge instructed the jury that they 
were permitted to accept the diagnosis of brain death for 
the purpose of organ retrieval. In 1981 the report of the 
Medical Consultants on the Diagnosis of Death to the 
President's Commission for the Study of Ethical 
Problems in Medicine and Biomedical and Behavioural 
Research 7 was published. This document defined criteria 
for death and clarified guidelines to enable doctors to 
declare a potential donor as brain dead. Long distance 
procurement coordinated by national transplant centres 
made heart transplantation possible on a wider scale 8.9. 
In 1980, fewer than 360 heart transplants had been 
performed. By 1993, the Registry of the International 
Society for Heart Transplantation reported 229 active 
centres and 22,400 heart transplants 10. Thirty years on, 
clinical human transplantation has carved an important 
niche in an array of therapeutic options for end-stage 
heart failure. The more thorough investigation and 
utilisation of alternative treatments stems from a 
shortage of donor organs 11, that has led to a plateau in 
the number of transplants worldwide. In 1990, 30% of 
patients awaiting transplantation died before al) organ 
became available, a mortality risk exceeding that of 
having the procedure 12. 
Other surgical options include the latissimus dorsi 
cardiomyoplasty described by Carpentier 13 and more 
recently the cardiac remodeling procedure by Batista 14. 
Patients with evidence of active ischaemia should be 
considered for revascularisation even in the presence of a 
left ventricular ejection fraction (LVEF) under 25% 15. 
Cardiac assist devices, such as the Heartmate, originally 
employed for bridging to transplantation, are now being 
implanted as permanent devices 16.17 
Xenotransplantation, utilising the heart of a genetically 
engineered pig, is currently on hold because of fears of 
epizootic disease 18. Exciting advances in medical 
treatment with ACE-inhibitors 19.20.21, betablockers 22 
and pacing 23 promises improved quality and length of 
life for heart failure sufferers. Patients with sustained 
ventricular arrhythmias and a reduced L VEF should be 
considered for implantation of a defibrillator24 . 
Heart transplantation still provides the best outcome 
and 5 year survival in established centres now 
approximates 65% 25. The immediate success of surgery 
is directly related to the correct choice of the ideal donor 
and recipient. In larger centres with a vast waiting list 
such a match is 'more likely. Smaller centres are 
handicapped by a paucity of donors and a lack of 
effective bridging cardiac assist devices. This increases 
the likelihood of a prospective recipient dying while 
waiting. In these circumstances pressure to transplant 
encourages a less than ideal match. The presence of 
pulmonary hypertension remains the single most 
important risk factor for early death after transplant 26. 
Our position in Malta is typical of a small isolated unit. 
A 19 year old male patient died last year awaiting 
transplantation, and our third transplantee who 
underwent bypass surgery one year previously, died of 
acute pulmonary hypertension having received the heart 
of an older donor. A good match yields gratifying results 
as evidenced by our first two recipients who are likely to 
continue to enjoy a good quality of life for years to come. 
Transplantation remains a fascinating concept. There 
are some who believe that certain character traits of the 
donor may live on in the recipient. Recipients have 
occasionally been overcome by a strong urge to trace 
their donor and make contact with surviving relatives. 
Other recipients experience a depressive phase, feeling 
they are undeserving of a new lease of life brought about 
by another individual's tragic demise. The prospect of a 
permanent implantable device may solve these as well as 
other issues complicating transplantation. However, for 
the foreseeable future, transplantation is here to stay. 
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